 |
|
OverviewAt Adnexus, we are developing a novel, proprietary drug class that we call Adnectins™, which we believe possess competitive therapeutic, manufacturing and commercial advantages over traditional targeted therapeutic classes, such as antibodies and small molecules. We generate Adnectins by applying PROfusion™, our proprietary protein engineering system. PROfusion allows us to engineer trillions of Adnectin amino acid sequences at a time and to test and identify those sequences that will offer the most attractive drug properties. Together, Adnectins and PROfusion enable design and development of innovative targeted therapeutics. Click below to learn more about Adnectins and about PROfusion: |